Siro Perez helped set up the biotech startup while he was partner at IP Group in Australia.
Siro Perez, a former partner of university spinout investor IP Group in Australia, has become CEO of Rage Bio, a spinout that he co-founded.
Rage Bio was launched by IP Group Australia together with Australian universities and medical research institutes. Originating from Monash University, the company has developed splice-switching oligonucleotide therapeutics for the treatment of COPD and other inflammatory lung diseases.
Perez was head of life sciences in Asia-Pacific for IP Group in Australia for seven years. Before joining the VC firm, Perez co-founded and led three startups. He was also co-founder and operating partner at Hadean Ventures, a European life science VC fund manager.
In addition to naming Perez as CEO, Rage Bio announced a AU$29m ($19m) series A funding round, co-led by IP Group Australia and Hostplus, with participation from Monash Ventures, a VC fund that invests in spinouts from Monash University.
